| Literature DB >> 15325535 |
Robert M Lawrence1, Ruth A Lawrence.
Abstract
Three viruses (CMV, HIV, and HTLV-I) frequently cause infection or disease as a result of breast-milk transmission. Reasonable guidelines have been pro-posed for when and how to avoid breast milk in the case of maternal infection. For other viruses, prophylactic immune therapy to protect the infant against all modes of transmission are indicated (VZV, varicella-zoster immunoglobulin, HAV and immunoglobulin, HBV, and HBIg + HBV vaccine). In most maternal viral infections, breast milk is not an important mode of transmission, and continuation of breastfeeding is in the best interest of the infant and mother (see Tables 2 and 3). Maternal bacterial infections rarely are complicated by transmission of infection to their infants through breast milk. In a few situations, temporary cessation of breastfeeding or the avoidance of breast milk is appropriate for a limited time (24 hours for N gonorrheae, H infiuenzae, Group B streptococci, and staphylococci and longer for others including B burgdorferi, T pallidum, and M tuberculosis). In certain situations, prophylactic or empiric therapy may be advised for the infant (eg, T pallidum, M tuberculosis, H influenzae) (see Table 1). Antimicrobial use by the mother should not be a reason not to breastfeed. Alternative regimens that are compatible with breastfeeding can be chosen to treat the mother effectively. In most cases of suspected infection in the breastfeeding mother, the delay in seeking medical care and making the diagnosis means the infant has been ex-posed already. Stopping breastfeeding at this time only deprives the infant of the nutritional and potential immunologic benefits. Breastfeeding or the use of expressed breast milk, even if temporarily suspended, should be encouraged and supported. Decisions about breast milk and infection should balance the potential risk compared with the innumerable benefits of breast milk.Entities:
Mesh:
Year: 2004 PMID: 15325535 PMCID: PMC7133241 DOI: 10.1016/j.clp.2004.03.019
Source DB: PubMed Journal: Clin Perinatol ISSN: 0095-5108 Impact factor: 3.430
Breastfeeding issues for selected bacterial maternal infections
| Organism | Predominant modes of transmission | Usual timing of infection | Evidence for transmission in breast milk | Clinical significance |
|---|---|---|---|---|
| Food-borne | NA | None | BF/BM | |
| Toxin-mediated disease | ||||
| Contact-genital, secretions | Perinatal | None | BF/BM | |
| Contact—GI tract or stool | Perinatal | None | BF/BM | |
| Contact | NA | None | Delay BF 24-hr therapy in mother; BM Rifampin prophylaxis for the infant. | |
| Droplets | ||||
| Contact—GI tract | Perinatal | None | BF/BM | |
| Food-borne | Postnatal | |||
| Airborne | Postpartum (perinatal and congenital are rare) | Only with TB | With active TB, delay BF for 14 days; maternal therapy or PI, BM. | |
| Mastitis and lesions on the breast | ||||
| Droplet | Infant—isoniazid prophylaxis. | |||
| Contact—genital, oral, rectal | Perinatal (postnatal is rare) | None | Ceftriaxone—no delay, BF / BM. | |
| Body fluids | Other medications—delay 24-hr maternal therapy, BM. | |||
| Contact | Postnatal | Lesions on the breast or mastitis | Delay 24-hr maternal therapy, BM. | |
| Contaminated, stored breast milk | Avoid BM with breast lesions or MRSA. | |||
| Coagulase- negative | Contact | Postnatal (premature, sick neonates; IV lines, antibiotics) | None | BF/BM |
| Group B | Contact—genital tract, secretions | Prenatal | Case reports, rare | Preventive therapy. |
| Perinatal | Delay 24-hr maternal therapy, BM. | |||
| Postnatal | Empiric prescription for infant |
This is a selected, limited list intended to consider some important bacteria that cause infection in the neonate or infant and possible issues related to breastfeeding and breast milk.
Abbreviations: BF, breastfeeding is appropriate; BM, expressed breast milk is appropriate; GI, gastrointestinal; IV, intravenous; NA, Not applicable; PI, period of infectivity; TB, tuberculosis.
Bacteria that cause various clinical illnesses in the infant and the mother; the specific illnesses are too numerous to list.
For breastfeeding and non-breastfeeding situations; does not include all possible or reported modes of transmission (airborne, body fluids, contact, droplet, food-borne).
Does not include all possible times of transmission. If “NA” the timing of infection is not associated frequently with pregnancy, delivery, or neonates and infants.
Notes the appropriateness of breastfeeding or use of breast milk when the mother has specific bacterial infection.
Refer to the text for explanation.
Breastfeeding issues for selected viral maternal infectionsa
| Virus | Predominant modes of transmission | Usual timing of infection | Evidence for transmission in breast milk | Clinical significance |
|---|---|---|---|---|
| Cytomegalovirus | Contact—body fluids | Congenital, perinatal, postnatal | Culture; CMV-DNA PCR | Full-term infants: BF/BM. |
| Premature, LBW, VLBW | ||||
| Enteroviruses (coxsackie virus, enterovirus, poliovirus) | Contact—fecal-Oral | Perinatal, postnatal | None | BF/BM |
| Hepatitis A | Food; water, contact—body fluids | Postnatal | One case report | BF/BM |
| Immunoglobulin | ||||
| Hepatitis B | Blood; body fluids; sexual | Perinatal | Hepatitis B Surface Antigen | Routine prevention with HBV vaccine and hepatitis B immunoglobulin, then BF/BM |
| Hepatitis C | Blood; body fluids | Prenatal, perinatal | ? Possible HCV-RNA | BF/BM (increased transmission if coinfected with HIV) |
| HSV1, HSV2 | Contact | Perinatal (congenital, postnatal) | Transfer only with breast lesions | BF/BM (except with breast lesions) |
| HIV1 | Blood; body fluids; sexual | Perinatal, prenatal, postnatal | HIV-RNA PCR; culture | Avoid BF/BM |
| HIV2 | Blood; body fluids; sexual | Prenatal, perinatal | Limited information | Avoid BF/BM (early weaning may be appropriate) |
| HTLV-I | Blood; body fluids | Postnatal, prenatal, perinatal | HTLV-I–RNA PCR | Avoid or limit BF/BM to less than 6 mo |
| Parvovirus | Contact; body fluids | Prenatal | Unknown | BF/BM |
| Respiratory syncytial virus | Droplets; contact | Postnatal (susceptible neonates and infants) | None; possible benefit of BM | BF/BM |
| Palivizumab | ||||
| Varicella-zoster virus | Contact; droplets | Postnatal (rare congenital or perinatal) | Only with lesions on breast; VZV-DNA | Avoid BF for PI |
| BM if no breast lesions Varicella-zoster immunoglobulin for infant |
This is a selected, limited list intended to consider some important viruses that cause infection in the neonate or infant and possible issues related to breastfeeding and breast milk.
Abbreviations: BF, breastfeeding; BM, expressed breast milk; HBV, hepatitis B virus; HCV, hepatitis C virus; LBW, low birth weight; PCR, polymerase chain reaction; PI, period of infection; VLBW, very low birth weight; VZV, varicella-zoster virus.
Viruses that cause a various of clinical illnesses in the infant and the mother; the specific illnesses are too numerous to list.
For breastfeeding and non-breastfeeding situations; does not include all possible or reported modes of transmission (airborne, body fluids, contact, droplet, food-borne).
Does not include all possible times of transmission.
Notes the appropriateness of breastfeeding or use of breast milk when the mother has a specific viral infection.
Refer to the text for more explanation.
CMV-positive breast milk should be avoided in these infants if they lack CMV-IgG. They are at greater risk to develop CMV-related disease.
Breast-fed infants who have received hepatitis B vaccine with or without hepatitis B immunoglobulin as indicated by maternal hepatitis B status are at no greater risk for HBV infection than formula-fed infants (who also should have received hepatitis B vaccine with or without hepatitis B immunoglobulin as indicated by maternal hepatitis B status).
Palivizamab is indicated for certain children at high risk for respiratory syncythial virus infection, regardless of feeding mode [16].
Breastfeeding issues for selected maternal infections
| Organism | Predominant modes of transmission | Usual timing of infection | Evidence for transmission in breast milk | Clinical significance |
|---|---|---|---|---|
| Contact—animals, animal products, cutaneous lesions; airborne | NA | None | BF/BM; cover lesions; medications for therapy and prophylaxis | |
| Arthropod | NA | DNA by PCR; no reports of illness in infants | BF/BM | |
| Contact | Postnatal (colonization, susceptible infants) | Contact with breast, not breast milk | BF/BM | |
| Dengue viruses (1–4) | Mosquito | NA | None | BF/BM |
| SARS-associated coronavirus | Contact; droplet | NA | None | BF/BM |
| Animal-borne; soil, fecal-oral | Congenital | None | BF/BM | |
| Body fluids; blood | Congenital, perinatal | None | Delay BF/BM 24-hr after initiating maternal therapy; empiric treatment of infant | |
| Vaccinia virus (smallpox vaccine) | Contact; possibly airborne | NA | One case report, contact with breast lesion | BF/BM |
| Variola virus (smallpox) | Contact; airborne | NA | None | Avoid BF/BM; separation PI |
| West Nile virus | Mosquito; blood | NA | One case report (no illness in infant) | BF/BM |
This is a selected, limited list intended to consider some important organisms that cause infection in the neonate or infant and possible issues related to breastfeeding and breast milk.
Abbreviations: BF, breastfeeding; BM, expressed breast milk; NA, not applicable; PCR, polymerase chain reaction; PI, period of infection; SARS, severe acute respiratory syndrome.
Organisms that cause various clinical illnesses in the infant and the mother; specific illnesses are too numerous to list.
For breastfeeding and non-breastfeeding situations; does not include all possible or reported modes of transmission (airborne, body fluids, contact, droplet, food-borne).
Does not include all possible times of transmission. If “NA,” the timing of infection is not associated frequently with pregnancy, delivery, or neonates and infants.
Notes the appropriateness of breastfeeding or use of breast milk when the mother has an infection with that specific organism.
Refer to reference [99].
Refer to the text for more explanation.